If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Adverse events more commonly observed with Dupixent (in at least 3 patients) compared to placebo included peripheral edema, arthralgia, back pain, blurred vision, hypertension, asthma ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

Do not change or stop your other medicines, including corticosteroid medicine or other asthma ... Dupixent® (dupilumab); the likelihood, timing, and scope of possible regulatory approval and ...

Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine ... including without limitation Dupixent® (dupilumab); the likelihood, timing, and scope of ...

which is already a $13.6 billion blockbuster from approved uses in diseases like atopic dermatitis and eosinophilic asthma. The other is chronic spontaneous urticaria (CSU), for which Dupixent was ...